Synartro reports last participant’s last visit (LPLV) in phase 1/2a clinical study of OA drug candidate SYN321

Uppsala, Sweden, February 18, 2026 - Synartro announces that the final study participant has completed the final follow-up visit in the phase 1/2a clinical trial of knee osteoarthritis drug candidate SYN321. 

Synartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical trial focused on safety, tolerability, PK, and early efficacy signals. The study was initiated in August 2025 and a total of 35 participants with knee osteoarthritis have participated.

All four cohorts were recruited and treated within a four-month period: cohort 1 (n=7), cohort 2 (n=8), cohort 3 (n=8), and cohort 4 (n=12). The highest dose tested in cohort 3 was selected for expansion in cohort 4. The final participant in cohort 4 completed the final follow-up visit in the first week of February.

Unblinding of the study is planned for the second week of March 2026, after which analyses of safety, tolerability, pharmacokinetics (PK) and efficacy data will be performed.

Interim safety observations

Interim data generated to date are consistent with preclinical observations. No serious adverse events related to the investigational medicinal product (IMP) have been reported. Observed adverse events are consistent with those commonly associated with intra-articular injections. No allergic reactions or immunological safety signals have been observed.

For further information, please contact:

Magnus Hurst, CFO & acting CEO. Tel: +46 (0) 760 27 44 27. E-mail: magnus.hurst@synartro.com

About Synartro AB

Synartro is a Swedish life science company developing local injection treatments that provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our proprietary slow-release technology with existing proven drugs. Our lead candidate drug SYN321 is a novel treatment of symptomatic osteoarthritis (OA). A disease that leaves hundreds of millions of patients without adequate pain relief.

In addition to the founders, major shareholders include life science investment company Linc AB.